After Japanese and Koreans, the efficacy and safety data of the conjugated monoclonal antibody Trastuzumab deruxtecan have now also arrived in Western patients with Her2 positive advanced gastric cancer. Results from the Phase 2 Destiny-Gastric02 study were presented by Daiichi Sankyo and AstraZeneca at the 2021 European Society of Medical Oncology Virtual Congress. Trastuzumab deruxtecan achieves a clinically meaningful and long-lasting tumor response in patients with metastatic gastric or gastroesophageal junction adenocarcinoma and / or unresectable Her2-positive, previously treated with a therapeutic regimen containing trastuzumab.
Random 2021
Metastatic breast cancer, monoclonal antibody triples survival
by Irma D’Aria
The neoplasm and the few chances of a cure
Gastric cancer is associated with a poor prognosis, particularly in the advanced stages of the disease, with only 5-10% of metastatic patients surviving for five years. About one in five gastric cancers are Her2-positive. After progression following first-line systemic anti-Her2 treatment, second-line treatment options in the metastatic setting are limited in some parts of the world.
Stomach cancer, 9 out of ten patients at risk for glycemic fluctuations
by Irma D’Aria
I study
In Destiny-Gastric02, the first study of trastuzumab deruxtecan specifically in Western patients with metastatic gastric cancer or Her2-positive gastroesophageal junction adenocarcinoma, the monoclonal antibody demonstrated a confirmed overall response rate of 38%, according to an evaluation of a independent central audit. Out of a total of 79 patients treated with trastuzumab deruxtecan, three (3.8%) complete responses and 27 (34.2%) partial responses were observed. These results are consistent with those of the pivotal phase 2 Destiny-Gastric01 study, previously published in The New England Journal of Medicine, which evaluated trastuzumab deruxtecan in Japanese and Korean patients with advanced Her2-positive advanced gastric or gastroesophageal junction adenocarcinoma two or more previous treatment regimens, including trastuzumab, a fluoropyrimidine, and platinum-containing chemotherapy.
Cancer of the esophagus, yes to immunotherapy to prevent recurrence
Response duration eight months
After a median follow-up of 5.7 months, the median duration of response for trastuzumab deruxtecan was 8.1 months. Median progression-free survival was 5.5 months. In addition, an exploratory endpoint of the confirmed disease control rate of 81% was observed. “These new efficacy data presented at the Esmo Congress in Paris – he commented Salvatore Siena, Professor of Medical Oncology at the University of Milan and director of the Falk Oncology Complex and of the Department of Hematology, Oncology and Molecular Medicine of the Niguarda Metropolitan Hospital – show that this therapy is the most powerful today ever achieved in the history of medical oncology for a tumor, Her2-positive gastric cancer not susceptible to surgical therapy, in a very difficult clinical situation, that is, after having failed the first line of medical oncological therapy “.
.